How Long Does It Take to Lose Weight On GLP-1 Injections? Real Expectations

If you are starting or considering a GLP-1 weight loss injection like Mounjaro or Wegovy, one of the first questions on your mind is probably how quickly you will see results. It is a completely natural thing to wonder, yet honest answers can be surprisingly hard to find online, where dramatic before-and-after stories and marketing claims often crowd out balanced information.

The reality is that weight loss on GLP-1 medications is a gradual process, and timelines vary considerably from one person to the next. What the clinical evidence does show is a fairly consistent overall pattern: appetite changes tend to come first, with meaningful weight loss building steadily over months rather than days or weeks.

This guide sets out what the trial data actually says about average weight loss over time, what can influence your own results, and what to do if progress slows. The aim is to give you realistic, evidence-based expectations rather than anecdote or hype.

What Does a Typical Weight Loss Timeline Look Like?

Most people do not start GLP-1 treatment at the full dose. Both Mounjaro and Wegovy are introduced gradually, stepping up if necessary over several weeks or months, which helps the body adjust and reduces the risk of side effects [1][2]. Because of this, the earliest weeks are often more about changes in appetite than dramatic changes on the scales.

In broad terms, many people notice reduced appetite and less preoccupation with food within the first few weeks. In the semaglutide STEP 1 trial, weight loss was measurable from the first assessment at week 4 and continued to build, reaching its lowest point at around week 60 [2]. Tirzepatide trials show a similar pattern of steady reduction over a period of around 72 weeks [1]. After the active weight loss phase, treatment typically moves into a maintenance stage focused on sustaining the results achieved.

The most important thing to hold onto is that these are averages. Some people lose weight more quickly, others more slowly, and individual results depend on a range of factors covered later in this guide. A slower start does not mean treatment is not working.

“One of the most important parts of weight loss treatment is setting realistic expectations from the start. Progress is rarely perfectly linear, and small fluctuations or plateaus are completely normal. Understanding this early helps patients stay motivated, avoid unnecessary disappointment, and focus on building healthy, sustainable habits that lead to long-term success.” Dr Saira Bano, GP at SwiftDoctor

How Long Does It Take for Mounjaro to Start Working?

Mounjaro (tirzepatide) is a dual-action medication that targets both GLP-1 and GIP receptors. Many people begin to notice appetite changes within the first few weeks of starting treatment, although the dose is increased gradually over time to balance effectiveness with tolerability [1].

In terms of overall results, the SURMOUNT-1 clinical trial provides the clearest picture. Over 72 weeks, adults with obesity or overweight (without type 2 diabetes) achieved an average weight loss of around 16% on the 5 mg dose, 21.4% on the 10 mg dose, and 22.5% on the 15 mg dose, compared with around 2.4% in the placebo group [3]. Higher maintenance doses were associated with greater average weight loss, which is part of why the dose is stepped up over time.

It is worth remembering that these figures are averages from a clinical trial in which treatment was combined with a reduced-calorie diet and increased physical activity [3]. Your own results will depend on your individual circumstances, which is why treatment should always be started and monitored with a qualified clinician.

How Long Does It Take for Wegovy to Start Working?

Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist. As with Mounjaro, appetite changes often appear in the early weeks, while the dose is gradually escalated to help reduce side effects [2].

The STEP 1 trial is the key source of evidence here. Over 68 weeks, adults with overweight or obesity (without type 2 diabetes) taking semaglutide 2.4 mg alongside lifestyle changes lost an average of around 14.9% of their body weight, compared with about 2.4% in the placebo group [4]. Weight loss was seen from the first assessment at week 4 and reached its greatest extent at around week 60 [2].

Compared with tirzepatide, the average weight loss reported in trials for semaglutide tends to be somewhat lower, though both are highly effective treatments with strong evidence behind them, and semaglutide has a slightly longer track record of use for weight management.

What Factors Affect How Quickly You Lose Weight?

No two people respond to GLP-1 treatment in exactly the same way, and several factors influence how quickly weight comes off. These include your starting weight, your diet, your activity levels, the dose you are on, and your individual metabolism [3][4]. The clinical trials consistently combined medication with reduced-calorie eating and increased physical activity, which reflects how these treatments are intended to be used.

One of the most useful mindset shifts is to stop measuring your progress against other people. Social media before-and-after photos rarely tell the full story, and they say nothing about a particular individual's starting point, dose, or health circumstances. Comparing yourself to them is not a reliable measure of whether your own treatment is working.

It also helps to focus on the bigger trend rather than day-to-day or even week-to-week fluctuations. Body weight naturally varies for all sorts of reasons, including hydration, hormones and digestion. Looking at your average trajectory over a month or more gives a far more accurate sense of progress than any single reading.

What If My Weight Loss Slows Down or Plateaus?

Reaching a plateau can feel discouraging, but it is a normal and well-recognised part of the weight loss process. A period where the scales stall does not necessarily mean treatment has stopped working, and it does not mean you have done anything wrong.

There are several things that may help when progress slows. Reviewing your diet and activity levels can be a useful starting point, as habits sometimes drift gradually over time. Your clinician may also discuss whether a dose adjustment is appropriate. At SwiftDoctor, the dose is only increased if someone has reached a plateau in their weight loss and needs a higher dose, rather than being escalated automatically. Any change should always be guided by a qualified clinician.

This is exactly where ongoing clinical support proves its value. Having a clinician review your progress and help you navigate a plateau, as part of SwiftDoctor's wider weight loss service, is far more constructive than trying to troubleshoot alone.

How SwiftDoctor Supports You Throughout Your Treatment Journey

Successful weight loss with GLP-1 medication is about much more than the initial prescription. SwiftDoctor provides ongoing clinical support throughout treatment, not just at the start, which is an important part of achieving and sustaining results.

That means clinicians can review your progress over time, adjust your dose where it is clinically appropriate, and offer guidance if your results are not what you expected. Because realistic expectations and steady support genuinely go hand in hand, having a clinician in your corner can make a meaningful difference to how you experience treatment, particularly through the inevitable ups and downs.

If you have questions about what to expect or how treatment is monitored, speaking to a qualified healthcare professional is always the best starting point.

Frequently Asked Questions

How much weight can I expect to lose in the first month on Mounjaro?

The first month usually focuses on appetite changes rather than dramatic weight loss, partly because the dose is still being increased gradually [1]. While some early weight loss is common, the larger reductions seen in trials built up over many months [3]. It is best to view the first month as the beginning of a longer process rather than a measure of final results.

Is it normal not to lose weight in the first few weeks?

Yes. Because GLP-1 doses are escalated slowly, it is common for the early weeks to bring noticeable appetite changes before significant weight loss appears [1][2]. A slow or modest start does not mean the treatment will not work for you. If you have concerns about your progress, it is worth discussing them with your clinician.

How does Wegovy weight loss compare to Mounjaro over time?

In the first head-to-head trial (SURMOUNT-5), tirzepatide led to greater average weight loss than semaglutide over 72 weeks, with an average reduction of around 20.2% compared with 13.7% [5]. Both remain highly effective treatments, and the most suitable option depends on individual circumstances, which is why this decision should be made with a clinician.

What should I do if my weight loss has stalled?

Plateaus are a normal part of weight loss and do not necessarily mean treatment has stopped working. Reviewing your diet and activity, and discussing whether a dose adjustment is appropriate with your clinician, can help. At SwiftDoctor, the dose is only increased if your weight has plateaued and needs a higher dose. Avoid making changes to your treatment without clinical guidance.

How long should I stay on GLP-1 medication for?

There is no single answer, as the right duration depends on your individual goals, response and health circumstances. GLP-1 treatments are generally used as part of long-term weight management, and stopping can lead to weight regain in some people. The decision about how long to continue should be made together with a qualified healthcare professional based on your own situation.

Sources

[1] National Institute for Health and Care Excellence (NICE), “Tirzepatide for managing overweight and obesity”, https://www.nice.org.uk/guidance/ta1026

[2] Wilding JPH et al., New England Journal of Medicine, “Once-Weekly Semaglutide in Adults with Overweight or Obesity” (STEP 1), https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

[3] Jastreboff AM et al., New England Journal of Medicine, “Tirzepatide Once Weekly for the Treatment of Obesity” (SURMOUNT-1), https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

[4] Eli Lilly and Company, “SURMOUNT-1 results published in The New England Journal of Medicine”, https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine

[5] Aronne LJ et al., New England Journal of Medicine, “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity” (SURMOUNT-5), https://www.nejm.org/doi/full/10.1056/NEJMoa2416394